| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1003590641 |
| P356 | DOI | 10.1111/J.1523-1755.2004.00735.X |
| P8608 | Fatcat ID | release_bdolmcy3mvfx3ntgij2t3nak2i |
| P698 | PubMed publication ID | 15200441 |
| P5875 | ResearchGate publication ID | 8508109 |
| P2093 | author name string | Anders Hartmann | |
| Torbjørn Leivestad | |||
| Aksel Foss | |||
| Per Fauchald | |||
| Kåre Osnes | |||
| Halvor Rollag | |||
| Solbjørg Sagedal | |||
| Miklos Degré | |||
| Knut P Nordal | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Cytomegalovirus | Q6946 |
| cytomegaloviral disease | Q2076966 | ||
| P304 | page(s) | 329-337 | |
| P577 | publication date | 2004-07-01 | |
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival | |
| P478 | volume | 66 |
| Q33871850 | A Systematic Review and Meta-analysis of Prophylactic versus Pre-emptive Strategies for Preventing Cytomegalovirus Infection in Renal Transplant Recipients |
| Q36994746 | A case report of CMV lymphadenitis in an adult kidney transplant recipient |
| Q59355818 | Aberrant regulation of the Akt signaling network by human cytomegalovirus allows for targeting of infected monocytes |
| Q36433529 | Acceleration of allograft failure by cytomegalovirus |
| Q40425776 | Adaptive NKG2C+ NK Cell Response and the Risk of Cytomegalovirus Infection in Kidney Transplant Recipients. |
| Q37965695 | Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy |
| Q30438204 | Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation |
| Q30427039 | Associations of pretransplant serum albumin with post-transplant outcomes in kidney transplant recipients |
| Q35124583 | Blood dendritic cell levels associated with impaired IL-12 production and T-cell deficiency in patients with kidney disease: implications for post-transplant viral infections. |
| Q51873058 | CMV infection in the donor and increased kidney graft loss: impact of full HLA-I mismatch and posttransplantation CD8(+) cell reduction. |
| Q43583466 | CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages. |
| Q37318303 | Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients |
| Q39009557 | Chronic allograft injury: Mechanisms and potential treatment targets |
| Q39502888 | Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: a 10-year experience |
| Q38849979 | Comparative Effectiveness of Tacrolimus-Based Steroid Sparing versus Steroid Maintenance Regimens in Kidney Transplantation: Results from Discrete Event Simulation |
| Q64062500 | Comparison of Transplant Outcomes for Low-level and Standard-level Tacrolimus at Different Time Points after Kidney Transplantation |
| Q36288594 | Correlation and clinical utility of pp65 antigenemia and quantitative polymerase chain reaction assays for detection of cytomegalovirus in pediatric renal transplant patients |
| Q57515316 | Cost analysis in favor of a combined approach for cytomegalovirus after kidney transplantation: a single-center experience |
| Q47287887 | Cost-Effectiveness Analysis of Everolimus versus Mycophenolate in Kidney Transplant Recipients Receiving No Pharmacological Prophylaxis for Cytomegalovirus Infection: A Short-Term Pharmacoeconomic Evaluation (12 Months). |
| Q59330226 | Cyclophilin A as a target in the treatment of cytomegalovirus infections |
| Q42278126 | Cytomegalovirus & Epstein Barr Virus serostatus as a predictor of the long-term outcome of kidney transplantation |
| Q42872370 | Cytomegalovirus Serostatus Pairing and Deceased Donor Kidney Transplant Outcomes in Adult Recipients With Antiviral Prophylaxis |
| Q42757541 | Cytomegalovirus and anemia: not just for transplant anymore |
| Q54464690 | Cytomegalovirus infection and disease following renal transplantation: preliminary report of incidence and potential risk factors. |
| Q35878194 | Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients |
| Q43549313 | Cytomegalovirus infection in kidney transplant recipients: Evolution of approach through three eras |
| Q42250541 | Cytomegalovirus infection in renal transplant recipients: one center's experience |
| Q36266751 | Cytomegalovirus latency promotes cardiac lymphoid neogenesis and accelerated allograft rejection in CMV naïve recipients |
| Q41342348 | Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice |
| Q42281180 | Cytomegalovirus prophylaxis in pediatric kidney transplantation: the Dutch experience. |
| Q37414600 | Cytomegalovirus reactivation in critically ill immunocompetent patients |
| Q37778827 | Cytomegalovirus-associated renal allograft rejection: new challenges for antiviral preventive strategies |
| Q34427661 | Cytomegalovirus-responsive γδ T cells: novel effector cells in antibody-mediated kidney allograft microcirculation lesions |
| Q88649024 | De Novo Urologic Malignancies in Renal Transplant Recipients |
| Q37680941 | Defining the risks for cytomegalovirus infection and disease after solid organ transplantation |
| Q33911369 | Delayed-onset cytomegalovirus disease coded during hospital readmission after kidney transplantation |
| Q46764122 | Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation |
| Q26863724 | Direct and Indirect Effects of Cytomegalovirus-Induced γδ T Cells after Kidney Transplantation |
| Q39162642 | Dual Role of Natural Killer Cells on Graft Rejection and Control of Cytomegalovirus Infection in Renal Transplantation. |
| Q40655846 | Effects of Granulocyte and Monocyte Adsorptive Apheresis in Renal Transplantation Recipients With Concomitant Cytomegalovirus Infection. |
| Q64105631 | Enhancement of Cytomegalovirus-Specific Cytokine Production after Modulation of the Costimulation in Kidney Transplant Patients |
| Q43523397 | Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation. |
| Q83396320 | Excellent results with high-dose mizoribine combined with cyclosporine, corticosteroid, and basiliximab in renal transplant recipients: multicenter study in Japan |
| Q44738359 | Exposure to mycophenolic acid better predicts immunosuppressive efficacy than exposure to calcineurin inhibitors in renal transplant patients. |
| Q84859127 | Ganciclovir transiently attenuates murine cytomegalovirus-associated renal allograft inflammation |
| Q92503320 | HLA-E Polymorphism Determines Susceptibility to BK Virus Nephropathy after Living-Donor Kidney Transplant |
| Q40590036 | Herpesvirus Respiratory Infections in Immunocompromised Patients: Epidemiology, Management, and Outcomes. |
| Q40232106 | High human cytomegalovirus DNAemia early post-transplantation associates with irreversible and progressive loss of renal function - a retrospective study |
| Q26850340 | Human CMV-specific T-cell responses in kidney transplantation; toward changing current risk-stratification paradigm |
| Q33747809 | Human Cytomegalovirus Induces TGF-β1 Activation in Renal Tubular Epithelial Cells after Epithelial-to-Mesenchymal Transition |
| Q52656958 | Human Cytomegalovirus Infection Increases Both Antibody- and Non-Antibody-Dependent Cellular Reactivity by Natural Killer Cells. |
| Q63740474 | Human Vascular Pericytes and Cytomegalovirus Pathobiology |
| Q34613091 | Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection |
| Q40267366 | Impact of Everolimus and Low-Dose Cyclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation. |
| Q42202589 | Impact of Pharmacist Involvement in Early Identification and Enrollment in Patient Assistance Programs on CMV Outcomes in Transplantation |
| Q34077023 | Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes |
| Q44407642 | Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial |
| Q37065216 | Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences |
| Q37668566 | Induction immunosuppression for orthotopic heart transplantation: a review |
| Q38858892 | Infection rates in tacrolimus versus cyclosporine-treated pediatric kidney transplant recipients on a rapid discontinuation of prednisone protocol: 1-year analysis |
| Q42286799 | Infections related to renal transplantation requiring intensive care admission: a 20-year study |
| Q46966037 | Influence of cytomegalovirus disease on early and late renal graft function |
| Q45431446 | Is there a link between cytomegalovirus infection and new-onset posttransplantation diabetes mellitus? Potential mechanisms of virus induced beta-cell damage |
| Q36516318 | Latent cytomegalovirus infection is an independent risk factor for late graft failure in renal transplant recipients |
| Q59340245 | Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial |
| Q46613226 | Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil |
| Q54237859 | Levels of anti-CMV antibodies are modulated by the frequency and intensity of virus reactivations in kidney transplant patients. |
| Q38259217 | Liver disease in kidney transplant recipients |
| Q37153873 | Long-term follow-up of kidney transplant recipients: comparison of hospitalization rates to the general population |
| Q30278721 | Long-term impact of CMV infection on allografts and on patient survival in renal transplant patients with protocol biopsies |
| Q36200933 | Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation |
| Q38822159 | Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. |
| Q37803335 | Management of cytomegalovirus infection in solid organ transplantation |
| Q45905220 | Measuring T-cell responses against LCV and CMV in cynomolgus macaques using ELISPOT: potential application to non-clinical testing of immunomodulatory therapeutics. |
| Q63246845 | Mesangial cells, specialized renal pericytes and cytomegalovirus infectivity: Implications for HCMV pathology in the glomerular vascular unit and post-transplant renal disease |
| Q45361024 | Opportunistic posttransplantation virus infections in renal transplant recipients |
| Q42260573 | PD-1 analysis on CD28(-) CD27(-) CD4 T cells allows stimulation-independent assessment of CMV viremic episodes in transplant recipients |
| Q34592551 | PD-1 expression and IL-2 loss of cytomegalovirus- specific T cells correlates with viremia and reversible functional anergy |
| Q47766934 | Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients |
| Q36759073 | Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage. |
| Q53120860 | Preemptive therapy versus valgancyclovir prophylaxis in cytomegalovirus-positive kidney transplant recipients receiving antithymocyte globulin induction. |
| Q31012501 | Preemptive versus prophylactic protocol to prevent cytomegalovirus infection after renal transplantation: a meta-analysis and systematic review of randomized controlled trials |
| Q36293963 | Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients |
| Q43653857 | Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation. |
| Q85417735 | Prevalence and clinical impact of cytomegalovirus infection and disease in renal transplantation: ten years of experience in a single center |
| Q36777860 | Prevention and management of cytomegalovirus infection in solid-organ transplantation |
| Q36262672 | Primary Cytomegalovirus Infection in Seronegative Kidney Transplant Patients Is Associated with Protracted Cold Ischemic Time of Seropositive Donor Organs |
| Q40956620 | Prophylactic CMV therapy does not improve three-yr patient and graft survival compared to preemptive therapy. |
| Q44441505 | Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients |
| Q44003429 | Prophylaxis versus preemptive protocols for CMV: do they impact graft survival? |
| Q35051236 | Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. |
| Q46511557 | Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials |
| Q38127967 | Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation |
| Q41728131 | Rhabdomyolysis associated with cytomegalovirus infection in kidney transplant recipients |
| Q35988433 | Risk Factors for Graft Failure and Death following Geriatric Renal Transplantation |
| Q41892541 | Risk factors for cytomegalovirus disease in seropositive renal transplant recipients; a single-center case-controlled study |
| Q44838872 | Six-month low-dose valganciclovir prophylaxis in cytomegalovirus D+/R- kidney transplant patients receiving thymoglobulin induction |
| Q33561715 | Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection |
| Q84486735 | Strategies for prevention of cytomegalovirus infection in renal transplant patients |
| Q34455315 | Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation |
| Q37862743 | Surrogate markers of infection: interrogation of the immune system |
| Q26823023 | Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors |
| Q95835695 | The development and implementation of stewardship initiatives to optimize the prevention and treatment of cytomegalovirus infection in solid-organ transplant recipients |
| Q38254037 | The efficacy and cost-effectiveness of valacyclovir in cytomegalovirus prevention in solid organ transplantation |
| Q42248317 | The impact of early cytomegalovirus infection after kidney transplantation on long-term graft and patient survival |
| Q46332187 | The impact of pretransplantation serum albumin levels on long-term renal graft outcomes |
| Q38193954 | The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients |
| Q46025722 | The influence of cytomegalovirus infections on patient and renal graft outcome: a 3-year, multicenter, observational study (Post-ECTAZ Study). |
| Q42229846 | Universal valganciclovir prophylaxis significantly reduces episodes of first-year cytomegalovirus disease and biopsy-proven acute rejection in kidney transplant recipients. |
| Q37863894 | Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation |
| Q46921335 | Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation |
| Q37724248 | Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients. |
| Q41138391 | Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective |
| Q38087371 | Valganciclovir: therapeutic role in pediatric solid organ transplant recipients |
| Q64087419 | Very Early Cytomegalovirus Infection After Renal Transplantation: A Single-Center 20-Year Perspective |
| Q51594265 | Viral infection in renal transplant recipients. |
| Q38240085 | Viral surveillance and subclinical viral infection in pediatric kidney transplantation. |
| Q81699527 | [Ureterostomy cytomegalovirus infection presenting as stoma ulceration in a kidney allograft receptor: a case report] |
Search more.